-
Product Insights
Ocular Melanoma - Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
Anaplastic Large Cell Lymphoma (ALCL) - Drugs In Development, 2024
Empower your strategies with our Anaplastic Large Cell Lymphoma (ALCL) – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma, involving abnormal growth of immune cells called lymphocytes. ALCL can affect the lymph nodes, skin, and other organs, often presenting as swollen lymph nodes or skin lumps. Two main subtypes exist: one linked to a genetic mutation and the other associated with breast implants. Treatment...
-
Product Insights
Hypopharyngeal Cancer - Drugs In Development, 2024
Empower your strategies with our Hypopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end...
-
Product Insights
Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
Non-Small Cell Lung Carcinoma - Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...
-
Product Insights
Adenocarcinoma - Drugs In Development, 2024
Empower your strategies with our Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Adenocarcinoma is a type of cancer that starts in mucus-producing (glandular) cells. Many organs have these types of cells and adenocarcinoma can develop in any of these organs. The symptoms of adenocarcinoma will depend on which organ is affected by cancer. The patients may not experience any symptoms until the cancer is more advanced. The Adenocarcinoma drugs in development market research report provide...
-
Product Insights
Myelofibrosis - Drugs In Development, 2024
Empower your strategies with our Myelofibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Myelofibrosis is a rare bone marrow disorder where abnormal cells cause fibrous tissue buildup, impairing blood cell production. It's a type of myeloproliferative neoplasm, leading to an enlarged spleen, anemia, fatigue, and increased infection risk. JAK2, MPL, or CALR mutations often underlie this condition. Diagnosis involves blood tests, bone marrow biopsy, and imaging. Treatment aims to manage symptoms and might involve medications, blood...
-
Product Insights
Uveal Melanoma - Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...
-
Product Insights
Metastatic Biliary Tract Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Biliary Tract Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic biliary tract cancer, originating from bile duct cells, spreads to distant areas like the liver, lymph nodes, or lungs. Symptoms, like jaundice and abdominal pain, manifest late. Diagnosis entails imaging scans and biopsies. Treatment focuses on palliative care to alleviate symptoms and prolong life, employing chemotherapy, targeted therapies, or immunotherapy. Prognosis remains guarded due to advanced stage upon diagnosis...
-
Product Insights
Nonmelanomatous Skin Cancer - Drugs In Development, 2024
Empower your strategies with our Nonmelanomatous Skin Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nonmelanoma skin cancer comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), originating from skin cells other than melanocytes. Linked to sun exposure, these cancers often appear on sun-exposed areas. BCC, the most prevalent, usually presents as a pearly bump or a sore that doesn't heal. SCC may appear as a scaly patch or a firm, red nodule. While rarely...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.